Cecal necrosis and perforation with systemic chemotherapy.
D000328:Adult; D001215:Asparaginase / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy; D002429:Cecal Diseases / Q000139:chemically induced*; D002648:Child; D003561:Cytarabine / Q000627:therapeutic use; D003630:Daunorubicin / Q000627:therapeutic use; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D007416:Intestinal Perforation / Q000139:chemically induced*; D007938:Leukemia / Q000188:drug therapy; D008297:Male; D015122:Mercaptopurine / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D009336:Necrosis / Q000139:chemically induced*; D011241:Prednisone / Q000009:adverse effects / Q000627:therapeutic use; D013866:Thioguanine / Q000627:therapeutic use; D014750:Vincristine / Q000009:adverse effects* / Q000627:therapeutic use
D003561:Cytarabine; D014750:Vincristine; D015122:Mercaptopurine; D001215:Asparaginase; D013866:Thioguanine; D005472:Fluorouracil; D011241:Prednisone; D008727:Methotrexate; D003630:Daunorubicin